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The management of motility disorders in critical illness
Introduction
Hospital malnutrition remains a significant reality especially in the 
intensive care unit (ICU) patient.1 Malnutrition has been reported in 
20-50% of hospitalised patients and has been shown to increase 
morbidity, mortality, infection rates, length of hospital stay, 
institutionalization and healthcare costs.1,2 Early enteral nutrition 
(EN) in ICU has been shown to improve clinical outcomes, minimize 
infection-related complications, preserve gut epithelial cell mass 
and the function of the gut-associated lymphoid tissue which offers 
mucosal barrier protection against bacterial translocation and thus 
offering cost-saving benefits.3-5 International recommendations 
state that optimal EN should be initiated within 24 hours of ICU 
admission.5 A number of trials have, however, shown that most ICU 
patients never receive their calculated target calories via EN.4 
Gastrointestinal tract (GIT) dysmotility is a major obstacle in early, 
optimal EN delivery,3 since up to 60% of patients have been 
reported to experience motility disorders, necessitating the transient 
cessation of EN infusion.4 It has been further reported that high 
gastric residual volumes (GRV’s) decrease gastric EN delivery in the 
ICU and this occurs in 30-51% of patients.5 Patients with high GRV’s 
are at increased risk of aspiration, have longer ICU stays and higher 
mortality rates.5 Symptoms of EN intolerance include elevated GRV’s, 
bloating, nausea, vomiting, abdominal distention, diarrhoea, and 
patient discomfort.4 
 Normal GIT motility
The primary motor function of the GIT is mixing and propelling food 
particles at a rate that enhances contact time of nutrients with the 
mucosa to facilitate absorption of nutrients.6 GIT motor function is 
also responsible for peristalsis that cleanses the proximal intestine 
of residual food and bacteria that leads to stool formation and 
passing.3,7 The two major functional zones are the proximal region, 
comprising of the fundus and antrum, which acts as a reservoir 
and the distal region, comprising of the antrum and pylorus, which 
together with the proximal duodenum delivers chyme at a metered 
rate into the absorptive mucosa of the small intestine at a maximum 
nutrient delivery rate of 8.4-12.6 kJ/minute.6
GI motility is a complex function regulated by the central, autonomic 
and enteric nervous system (ENS) and modulated by regulatory GI 
peptides, neurotransmitters and hormones as well as food or chyme 
presence.3 
Normal GIT motility is crucial for EN delivery.7 Disordered gut motility 
leads to reduced contact time of nutrients with the mucosa and 
causes small intestinal bacterial overgrowth.7 This may lead to 
increased permeability of the mucosa and bacterial translocation, 
which leads to diarrhoea, dehydration, hypovolemia, the systemic 
inflammatory response syndrome, sepsis and multiple organ 
failure, including malnutrition.3 Of greatest concern is high gastric 
aspirates which may lead to aspiration pneumonia with increased 
length of hospital stay, increased hospital readmission, mortality and 
morbidity.3 Dysmotility may also affect the absorption and efficacy of 
medication in the critically ill.3
Abnormal GIT motility
Motility disorders are common in critical illness and can be limited 
to the stomach, small bowel, colon or it can involve the whole GIT.3 
Two major types of GI motility disturbances often described in 
critically ill patients are postoperative ileus and the motility disorders 
of critical illness.3 In addition some patients may also have primary 
or secondary disorders such as achalasia, gastroparesis or chronic 
intestinal pseudoobstruction.3 The aetiology of abnormal GI motility is 
multifactorial in the critically ill.3 The most readily recognized motor 
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dysfunctions that are present in ICU patients who are intolerant to 
EN are:6
• Reduced frequency and amplitude of antral contractions.
• Loss of gastric phase 3 activity.
• Disorganized duodenal phase 3 activity that promotes retrograde 
flow.
• Disturbed fundic motor activity leading to delayed relaxation in 
response to nutrient stimulation in the gut which promotes failure 
of redistribution of gastric content.
• Abnormal duodenal contractility which impairs clearance from 
the proximal duodenum.
• Heightened feedback from the small intestinal receptors 
These dysfunctions may be due to enhanced secretion of 
cholecystokinin particularly when high fat feeds are used. A potential 
role for peptide YY has also been identified.6
Factors that precipitate abnormal GI motility in critically ill patients 
include shock, impaired enteric nerve and smooth muscle 
function, traumatic injuries, inflammation brought on by cytokine 
activity, surgery, drugs, electrolyte disturbances, ischaemia, 
hypoxia, hyperglycaemia, dysregulation of gut hormones and 
neurotransmitters in the ENS, dysfunction of the pacemaker cells 
of the GI smooth muscles, the primary diagnosis, sepsis, increased 
intracranial pressure, respiratory failure, cardiac injury and 
administration of energy dense formulas.3-6 Medication, such as 
catecholamines, opioids and sedatives, is also known to influence 
GIT motility. 
Identification of GIT motility disorders
Early identification of abnormal GIT motility, by clinical and/or 
biochemical means, is crucial to prevent complications, unnecessary 
interruptions of EN, to guide therapy and improve outcome.3 
Bowel sounds
Traditional physical assessment included auscultation. The presence 
of bowel sounds is thought to be a key feature of a healthy GIT.8 This 
practise continues to be taught in nursing and medical education 
despite the lack of empirical evidence demonstrating clinical 
significance.8 Bowel sounds do not correlate with peristalsis, it can 
be absent, hypoactive or high pitched during ileus.3 Baid, reviewed 
the available literature from 1980 to 2009 regarding bowel sounds, 
abdominal examination and abdominal physical assessment and 
found varied and contradictory information regarding normal and 
abnormal bowel sounds. What was consistent in Baid’s review was 
that the absence of bowel sounds were considered to be abnormal.8 
Fairclough and Silk, as quoted by Baid, stated that auscultation does 
not contribute to assessment of abdominal disease unless other 
signs of acute abdomen are present, and that it is done only because 
of habit and tradition, rather than to diagnose or plan interventions.8
Gastric residual volume (GRV)
Measurement of GRV’s is the most widely used practise to assess 
gastric function in ICU patients receiving EN.3 This practise appears 
to lack standardization and is affected by patient positioning, 
technique, tube location and diameter.9 Correlation between GRV’s 
and gastric emptying rate has not been adequately demonstrated; 
however it is still considered to be a likely indicator of retention of 
gastric content.3,9 Clinicians agree that large GRV’s are abnormal 
and can lead to aspiration, but no agreement has been reached on 
the definition of a “large” GRV.9 Johnson, has cautioned that large 
GRV’s are not always a sign of intolerance to EN and low GRV’s are 
not always proof of no risk of aspiration.9 McClave, as quoted by 
Johnson, stated: “No appropriate designated residual volume level 
to identify aspiration could be derived as a result of poor sensitivity 
over a wide range of residual volume.”9
GRV’s require accurate measurement, taking time and patience when 
being performed. Metheny, as quoted by Stambovsky, describes 
the technique they follow to measure accurate aspirates as the 
following: a 60 ml syringe is used and 30 ml of air is forced through 
the syringe prior to each aspiration attempt in order to force the 
tube’s ports away from the mucosal folds. This process is repeated 
two to three times during each measurement attempt. Slow and 
gentle withdrawal of the plunger after each air insufflation works 
best.10 Regarding GRV cut off, published reports vary from 200 to 
500 ml with the lower limit based on assumptions that all GRV’s are 
aspirated.9 McClave et al, as quoted by Johnson, showed that more 
than 90% of patients had GRV’s of 150 ml or less, thus the question 
was posed whether all aspirates had been drawn.9 
Stroud, as quoted by Johnson, showed that GRV’s are higher at the 
start of EN.9 Johnson stated high GRV’s at the beginning of EN should 
not lead to feeding cessation, except if other signs of intolerance such 
as bloating, abdominal pain, emesis or nausea appear.9 Parrish et al, 
as quoted by Johnson, stated that consistently low GRV’s after 48-72 
hours of successful EN indicate that testing is no longer necessary.9 
Monitoring of GRV’s, alone should, therefore not be used solely to 
monitor the risk of aspiration. Measures to decrease the latter, such 
as elevating the head of the patient’s bed to 30-45 degrees, using 
medication to promote motility and postpyloric feeding should also 
be considered.9
Landzinski et al did a study to compare gastric emptying using the 
paracetamol absorption test (PAT), in patients with low and high GRV’s 
in order to determine if prokinetic therapy improves gastric motility 
in patients with intolerance. The authors reported that elevated 
GRV in ICU patients during gastric EN is associated delayed gastric 
motility. A set protocol for GRV measurement by means of the syringe 
technique and an 18-Fr large diameter tube was used. Prior to the 
enrolment of patients correct antral positioning of the gastric tube 
was determined by auscultating over the stomach after injecting air 
and confirmed radiographically. The use of GRV’s did yield accurate 
indications of gastric motility delay.5 The clinical significance of the 
latter, part from inadequate EN feeding, is the findings of Inglis et al, 
as quoted by Landzinski, who found higher rates of Gram-negative 
bacilli in both gastric and tracheal aspirates with impaired motility, 
highlighting the risk for infection.5
The evidence regarding GRV assessment is thus not clear but 
large GRV’s at the beginning of EN feeding should mandate further 
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investigation and therapeutic measures should be taken to prevent 
aspiration and resultant complications.
Paracetamol absorption test (PAT)
PAT, also known as the acetaminophen absorption test (AAT), has 
successfully been used in the ICU setting.3 The test is based on 
pharmacokinetics indicating that the drug is not absorbed from the 
small bowel.3 Good correlation has been found between stomach 
emptying time and peak plasma concentrations of paracetamol.3,5 
PAT is an indirect method to measure gastric emptying, but not 
small bowel motility.3 Rapid stomach emptying is associated with 
increased drug absorption from the small intestine and early peak 
plasma concentrations of paracetamol.3 PAT results should be 
obtained from patients with nasogastric or gastric feeding tubes 
rather than small bowel feeding tubes.3 First pass metabolism, 
distribution, elimination and alterations in gut integrity will affect 
plasma levels of paracetamol.3 Although PAT is safe, low cost 
and feasible to perform in the ICU, it does not require multiple 
blood sampling and personnel assistance. Contraindications for 
PAT include hypersensitivity to paracetamol, severe hepatic and 
renal impairment, severe malnutrition as well as long term use of 
ethanol, rifampin, carbamazepine and phenytoin. Results in patients 
with upper GI surgery are not accurate as these procedures alter 
the rate of absorption. Aspiration of gastric content can also alter 
the absorption kinetics of the drug leading to inaccurate results.3,4 
Heyland et al, as quoted by Landzinski et al, demonstrated by using 
PAT that critically ill patients, when compared with healthy controls, 
have delayed gastric emptying.5
Gastric scintigraphy, the breath test, ultrasonography and magnetic 
resonance imaging, gastric motility recording and measurement of 
small bowel motility are other tests that have been described in the 
literature. However all of these are not considered routine practice 
due to such limilations as time, test availability, need for normal 
organ function other than GIT and cost.3 
Treatment of GIT dysmotility in critical illness
From the treatment point of view the first and easiest intervention is to 
correct fluid and electrolyte disorders by means of correct hydration 
of the correct spaces, as well as decreasing or discontinuing 
drugs, when possible, that are known to slow down GIT motility.4 
Furthermore, the use of an EN feeding protocol and jejunal feeding 
to prevent duodeno-gastric reflux is advised.5,10 Other interventions 
include:
Blood glucose control with continuous insulin 
Hyperglycaemia, even at levels of 7.8 mmol/l has been shown to 
disrupt antral motor activity.3 Reduced fundic tone, inhibition of 
antral pressure waves and stimulation of pyloric pressure waves has 
been observed with glucose levels above 15 mmol/l.3 This is due 
to reduced vagal efferent activity and nitric oxide release from the 
myoenteric plexus which is only seen with solids and not with liquids.3 
A number of studies showed that blood glucose concentrations are 
a positive predictor of delayed gastric emptying. By reducing fasting 
blood glucose from 10.6 mmol/l to 8.6 mmol/ or post prandial blood 
glucose from 15.5 mmol/l to 9.4 mmol/l for instance, can increase 
gastric emptying rate by almost 20%, with accompanying increase 
in the number of gastric contractions.4 To date there is no certainty 
that this magnitude of improvement may be found in ICU or is of 
documented clinical significance.4
Motility agents
The International Nutrition Survey in 2009 showed 66% of individuals 
with high GRV’s receive motility agents.10 The best hospital settings 
provided motility agents to patients 100% of the time and the lowest 
performing sites never gave motility agents.10 Motility agents have 
been shown to improve gastric emptying, improve tolerance to EN 
as well as increase nutritional adequacy and reduce the energy debt 
of underfeeding.10 
Metoclopramide, a 5HT4 receptor agonist is the most widely 
used prokinetic agent in patients with feeding intolerance.6 This 
drug stimulates gastric and duodenal motility.6 Metoclopramide 
10 mg IV given 6 hourly may be effective in treating enteral nutrition 
intolerance.6 However the effects of the drug rapidly diminish over 
time such that by day 3 the feeding success in patients with high 
GRV’s is less than 20%.6 Ukleja recommends that this dose should 
be halved in renal failure.3 Metoclopramide is not effective in patients 
with brain injury.6 Side effects include dystonic reactions.3
Erythromycin, a macrolide antibiotic was first established as a 
potential gastrokinetic agent in the early 1990’s.6 Erythromycin 
at 200 mg IV 12 hourly can be used prophylactically in high risk 
patients or reactively when high GRV’s are seen.6 However as in 
the case of Metoclopramide prolonged administration has been 
associated with reduced efficacy. Only 30% of patients by day 7 
of treatment were still tolerant to EN.6 IV erythromycin needs to 
be diluted depending on dosage and its use may therefore be of 
limited value in fluid restricted patients.6 Efficacy and side effects 
of erythromycin are inversely proportionate to dosage and exact 
dosage for enteral nutrition tolerance has not been adequately 
described.4 Side effects include increases in clinical effects of many 
drugs including cyclosporine, tacrolimus, methadone and fentanyl.3 
It is also important to note that neither of these drugs have been 
approved by the FDA for use in ICU to reverse EN intolerance.4 
This off-label use is extrapolated from their established efficacy in 
treating diabetic gastroparesis.4 The two drugs can be used alone or 
in combination to achieve maximal effects.6,10 The mechanism of the 
claimed synergistic effect is unclear but may reflect the blockade of 
alternative compensatory pathways.6 Discontinuation is needed if no 
treatment effect is found.10
Landzinski et al’s study to evaluate prokinetic usage after gastric 
dysmotility, confirmed that patients with elevated GRV’s definitely 
had impaired gastric emptying compared with patients with minimal 
GRV’s. Secondly initiating prokinetic therapy in patients with elevated 
GRV’s accelerated gastric motility to the extent that gastric emptying 
function resembled that of patients tolerating EN. Their findings on 
beneficial effect was overall in favour of erythromycin.5 Landzinski’s 
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findings extended the findings of other similar trials including that 
of Cohen et al, as quoted by Landzinski who reported that initiating 
prokinetic therapy led to the initiation of EN in 88% of their patients.5 
In the case of Landzinski EN initiation was achieved in 100% of their 
patients, but difference in the extent of EN initiation may have been 
due to study design.5 According to Landzinski, the optimal role of 
prokinetic agents in patients experiencing EN intolerance remains 
to be determined.5 
Complementary and alternative medicines
Mullin and Clarke did a recent review of complementary and 
alternative medicine and their role in the treatment of motility 
disorders. They stated that western based herbs such as peppermint 
oil, caraway oil, ginger and STW5 (Iberogast) as well as Chinese 
herbs like TWK, electroacupuncture as well as neutraceuticals like 
melatonin and hypnosis in the form of music therapy can modulate 
GI motility.7 The safety or efficacy of such treatments have not been 
shown, especially in critically ill patient and are not advocated. 
The authors warn that practitioners need to become more aware 
of these treatments because of their potential adverse effects. 
Cinnamon, for instance, at a dose of more than 6 g per day may lead 
to delayed gastric emptying, an effect that may be potentially useful 
in the management of patients with the dumping syndrome.7 The 
use of such alternative therapies may therefore be associated with 
unplanned treatment effects and are not recommended until their 
effects are well documented. 
Future treatments
Cholecystokinin antagonists may be a possible futuristic approach as 
cholecystokinin levels are increased in patients with enteral feeding 
intolerance.6 Agonists and other hormones such as ghrelin may also 
be investigated to promote gastric motility and positively influence 
metabolism via growth hormone secretion.6
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